|
Pigment Dispersion Syndrome With and Without Glaucoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Pigment Dispersion Syndrome With and Without Glaucoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Pigment Dispersion Syndrome With and Without Glaucoma Clinical research trials and Pigment Dispersion Syndrome With and Without Glaucoma health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Pigment Dispersion Syndrome With and Without Glaucoma. Pigment Dispersion Syndrome With and Without Glaucoma Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Pigment Dispersion Syndrome With and Without Glaucoma clinical trial. Test subjects typically receive the most expert healthcare available for their Pigment Dispersion Syndrome With and Without Glaucoma condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pigment Dispersion Syndrome With and Without Glaucoma  Pigment Dispersion Syndrome With and Without Glaucoma
Pigment Dispersion Syndrome With and Without Glaucoma
For Condition: Glaucoma,Glaucoma, Open-Angle,Ocular Hypertension
Status: Completed
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: To compare patients having PDS without and with OH or GL by documenting and following the clinical features and course of their disease and evaluating the patient's performance on a variety of diagnostic tests.
Details: Pigment dispersion syndrome (PDS) is not an uncommon ocular condition and is frequently associated with myopia. There is loss of pigment from the posterior iris, seen clinically in most cases as iris transillumination with pigment deposited on the corneal endothelium, iris surface and on the angle structures overlying Schlemm's canal. In a subset of patients ocular hypertension or glaucoma may develop. Ocular hypertension is defined as 3 separate measurements of the intraocular pressure greater than 22 mm/Hg in the absence of visual field loss. Glaucoma is defined as the presence of a characteristic field defect (Bjerrum scotoma, nasal step or arcuate scotomas) with intraocular pressures greater than 22 mm/Hg measured sometime during a diurnal curve testing. The etiology of this condition is not known. Hypotheses include developmental abnormalities of the iris dilator muscle or mechanical rubbing of zonules against the iris, resulting in pigment dispersion in the anterior chamber and pressure elevation. PDS is then viewed as a variant of primary open-angle glaucoma or may be secondary to pigment deposited in the angle structures with secondary damage to the trabecular meshwork. A hereditary component does appear to play a role in the PDS syndrome and may also predispose to the development of glaucoma. The purpose of this study is to evaluate and determine the risk factors that differentiate patients with PDS, PDS+OH, or PDS+GL by documenting the ophthalmic findings and following their clinical course. In order to do this, diagnostic tests including intraocular pressure and visual fields will be performed. This data may make it possible to determine the risk of patients having PDS of developing OH, GL or other possibly associated findings such as retinal detachment or cataract. In addition, patients with "pigmentary glaucoma (PG)" will be compared to those with the known characteristics of primary open-angle glaucoma (POAG) to determine whether PG is different than or a variant of POAG. When possible, family members will be examined to investigate the inheritance pattern of this syndrome and its relationship to POAG.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Entrance into the study will depend upon clinical evidence of black pigment deposition on trabecular meshwork at the site of Schlemm's canal and at least one of the following: Kruckenberg spindle, pigment deposition on iris surface, or mid-stromal iris transillumination. No patients with other ocular disease or disorders (uveitis, trauma, pseudoexfoliation, ICE syndrome, etc.)
Total Enrollment: 175
Location and Contact Information:
National Eye Institute (NEI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 760189; 76-EI-0189
Study Start Date: June 16, 1976
Record last reviewed: May 18, 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001152
Other Ocular Hypertension Studies:
1. A 6-week safety & efficacy study of combination intraocular pressure-lowering therapy in patients with open-angle glaucoma or ocular hypertension
2. Phase IV study of TRAVATAN 0.004% in subjects with iris pigmentation changes
3. Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-02-41
4. A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients with Open-Angle Glaucoma or Ocular Hypertension
5. Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients with Glaucoma or Ocular Hypertension.
Related Studies:
Other Ocular Hypertension Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Pigment Dispersion Syndrome With and Without Glaucoma
|
|
|
|
|
|
|
|
